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Ras interacts with many downstream effectors that regulate complex cytoplasmic signaling 
networks. In this issue, Gupta et al. (2007) use mouse models of Ras-mediated tumorigenesis 
to show that the interaction of Ras with a single isoform of phosphatidylinositol 3-kinase 
(PI3K), called p110α (PIK3CA), is critical for tumor formation. This result will stimulate re-
evaluation of pharmacological approaches to target Ras for cancer treatment.At least 11 distinct functional classes 
of proteins—including the Raf serine/
threonine kinases and the p110 cata-
lytic subunits of class I PI3Ks—have 
been implicated as effectors of the 
small GTPase Ras (Repasky et al., 
2004). Because of the frequent muta-
tional activation of Ras in cancer and 
the vast number of its effectors (Fig-
ure 1), there has been much debate 
regarding the most effective strate-
gies to develop anti-Ras inhibitors. In 
this issue, Gupta et al. (2007) further 
validate the importance of p110α and 
the PI3K-Akt signaling pathway in 
Ras-induced tumorigenesis.
The majority of studies analyzing 
a role for effectors in Ras-mediated 
oncogenesis have been performed in 
cultured cells. For example, experi-
ments in immortalized human epi-
thelial cells ectopically expressing 
oncogenic Ras have shown that 
concurrent activities of Raf, PI3K, 
and Ral-GEF (guanine nucleotide 
exchange factor) effector pathways 
are required for Ras-mediated initia-
tion of tumor growth. The PI3K path-way is also crucial for tumor mainte-
nance (Lim and Counter, 2005). One 
recent study used RNA interference 
to demonstrate the necessity of the 
Ral-GEF-Ral pathway in tumorigene-
sis, invasion, and metastasis of KRAS 
mutation positive pancreatic carci-
noma cell lines (Lim et al., 2005).
Genetically engineered mouse 
models have also validated the impor-
tance of Ras effectors (Repasky et al., 
2004). Mice deficient for the effectors 
Tiam1, PLCε, or Ral-GDS showed 
impaired tumor initiation when tested 
in skin tumorigenesis—induced by the 
carcinogen dimethybenzanthracine 
(DMBA)—in which H-Ras activation is 
causal and frequent. Genetic ablation 
of other Ras effectors, in particular 
of p110α and p110β, results in defec-
tive development, thus complicat-
ing analyses of their contributions to 
Ras-mediated cancer development. 
Furthermore, deficiency studies can 
only assess the requirement of a given 
factor for tumorigenesis and not the 
specific interactions involved. Thus, 
Gupta et al. (2007) engineered mice in Cell 12which the endogenous PIK3CA gene 
encodes a mutant p110α protein that 
is enzymatically active, but cannot 
interact with Ras, to evaluate the role 
of this effector in endogenous normal 
and mutant Ras signaling.
To selectively ablate p110α inter-
actions with Ras, Gupta et al. (2007) 
introduced missense mutations into 
the germline sequence specifying the 
Ras-binding domain of p110α. Viable 
mice homozygous for this PIK3CA 
mutant allele were obtained, indi-
cating that this partial loss-of-func-
tion mutant of p110α was sufficient 
to support development. They then 
analyzed these PIK3CA mutants in 
two well-characterized Ras-driven 
tumor models. In the K-Ras LA2 
mouse model (Johnson et al., 2001), 
tumorigenesis is driven by endog-
enous levels of mutant K-Ras (G12D) 
expression, and these mice develop 
lung adenocarcinomas at a high fre-
quency. When the K-Ras LA2 mice 
were crossed with mice homozygous 
for mutant PIK3CA, a striking 95% 
reduction in lung tumor forma-9, June 1, 2007 ©2007 Elsevier Inc. 855
Figure 1. Effectors of Ras-Mediated Oncogenesis
Members of at least five functional classes of effectors have been implicated in Ras-mediated 
growth transformation and oncogenesis. The best studied is the Raf serine/threonine kinases 
(c-Raf-1, A-Raf, B-Raf). Raf phosphorylates and activates the MEK1 and MEK2 kinases, which 
phosphorylate and activate the ERK1 and ERK2 MAPKs. The next best characterized are the 
p110 (α, β, δ, and γ) catalytic subunits of the class I PI3Ks. PI3K kinases convert phosphati-
dylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3), which pro-
motes activation of multiple signaling proteins, including PDK1-mediated phosphorylation and 
activation of the AKT serine/threonine kinase. Four guanine nucleotide exchange factors (GEFs, 
which promote formation of the active, GTP-bound form of small GTPases) are activators of the 
RalA and RalB small GTPases (Ral-GDS, Rgl, Rgl2/Rlf, and Rgl3). The GEF Tiam1 (and the related 
Tiam2) activates the Rac small GTPase. Finally, Ras activation of phospholipase C epsilon (PLCε) 
catalyzes conversion of phosphatidylinositide (4,5) biphosphate to the second messengers, dia-
cylglycerol (DAG) and inositol (1,4,5)-triphosphate (IP3), resulting in DAG-mediated activation of 
protein kinase C (PKC) and mobilization of intracellular calcium ions, respectively.tion was observed. Second, when 
PIK3CA mutant mice were subjected 
to DMBA-induced carcinogenesis, a 
near-complete reduction in H-Ras-
driven tumor formation was seen. 
Taken together, these observations 
argue that p110α is a critical effector 
for Ras-driven tumorigenesis in two 
distinct tissues.
The interpretation of the Gupta 
et al. study may be complicated 
by the importance of normal Ras 
signaling through p110α in normal 
host tissue. Mice homozygous for 
mutant PIK3CA exhibited in the 
lymphatic vasculature defective 
branching that markedly reduced 
viability at birth. Interestingly, this 
defect is similar to one seen previ-
ously in vascular endothelial growth 
factor C heterozygous null mice. 
Because of potential abnormalities 
caused by the PIK3CA mutation, 
it is possible that reduced Ras-
driven tumor formation and growth 
in these mice may be partly due 
to altered responses of the tumor 856 Cell 129, June 1, 2007 ©2007 Elseviemicroenvironment. However, trans-
formation assays in PIK3CA mutant 
mouse embryo fibroblasts derived 
from homozygous PIK3CA mutant 
embryos showed resistance to Ras 
transformation unlike their wild-type 
counterparts supporting a cell-
autonomous effect on mutant Ras 
signaling.
The importance of PI3K effector 
signaling in Ras-induced tumorigen-
esis that is suggested by this study 
argues against the perception of 
the Raf-MEK-ERK pathway being of 
prime if not sole importance, a con-
cept that has been strengthened by 
the nonoverlapping frequency of 
RAS and BRAF mutations observed 
in melanomas and other cancers 
(Davies et al., 2002). In vitro experi-
ments demonstrated Ras activa-
tion of the Raf-MEK-ERK cascade in 
mouse embryo fibroblasts isolated 
from the p110α mutant mice. This 
result argues that, in this setting, 
Ras-mediated tumorigenesis cannot 
be driven by activation of Raf alone. r Inc.Alternatively, the effectors critical 
for Ras-induced tumorigenesis may 
be cell type specific, and Raf is not 
essential for lung adenocarcinoma 
development.
Another issue emphasized by this 
study is the functional diversity of the 
p110α and p110β isoforms, which are 
both Ras effectors, yet Gupta et al. 
reveal that p110β cannot efficiently 
support Ras-mediated activation of 
Akt. This observation mirrors those 
showing that Ras failed to effectively 
activate p110β in cell culture (Rodri-
guez-Viciana et al., 2004). Thus, in 
addition to the unique mutational 
activation of p110α but not p110β 
in human cancers (Samuels et al., 
2004), cell-culture and mouse-model 
studies have also identified functional 
differences between these related 
p110 isoforms.
This study prompts several impor-
tant future questions. First, will mice 
expressing Ras binding-deficient 
mutants of Tiam1, Ral-GDS, or PLCε 
show the same impaired Ras-induced 
tumorigenesis observed in mice defi-
cient in effector expression? A simi-
lar evaluation with mice expressing 
Ras binding-deficient Raf isoforms 
will also be important to pursue. 
Second, will Ras-driven oncogen-
esis in other mouse cancer mod-
els—in particular in K-Ras-induced 
pancreatic tumor formation models 
(Aguirre et al., 2003; Hingorani et 
al., 2003)—also require p110α? The 
obligatory role for K-Ras activation in 
pancreatic tumors, coupled with the 
lack of effective therapeutic options 
for this deadly cancer, emphasizes 
the need to understand Ras in this 
cellular context. Third, these stud-
ies address the importance of PI3K 
signaling in the initiation of tum-
origenesis. For effective therapy of 
pre-existing cancers, will the PI3K 
effector pathway also be required 
for tumor maintenance? This issue 
can be addressed by conditional 
expression of the mutant PIK3CA 
allele, which should reveal whether 
therapies targeted against PI3K and 
Akt (now entering clinical trials) will 
be an effective strategy for treating 
human cancers, particularly those of 
the lung, colon, and pancreas where 
RAS mutations are most prevalent. 
Recent results in human tumor cell-
culture models suggest that inhibi-
tion of the Raf-MEK-ERK cascade 
alone is not an effective strategy 
for treating tumors with RAS muta-
tions, and that perhaps concurrent 
inhibition of other effector pathways 
is needed. Finally, will these results 
from mouse models accurately 
reflect the mechanisms of Ras-medi-
ated oncogenesis in human tumors? 
Answers to these questions will be 
needed before the “right” strategy to 
target Ras signaling for cancer treat-
ment will be realized.Many living organisms have an internal 
clock that tracks the time of day even 
in the absence of external cues. This 
feat is accomplished by an internal 
transcription-translation-degradation 
cycle that is carefully tuned to produce 
circadian rhythms that are almost 24 
hr in length. Given that transcriptional 
regulation is tightly controlled by the 
clock, it is reasonable to assume that 
degradation should also be tightly 
controlled. A trio of recent papers now 
demonstrates how controlled degrada-
tion of a second key circadian regula-
tory protein is critical for proper clock 
function (Siepka et al., 2007; Godinho 
et al., 2007; Busino et al., 2007).
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Two members of the PERIOD family, 
PER1 and PER2, and two members of 
the cryptochrome family, CRY1 and 
CRY2, are core proteins in the mam-
malian clock. The transcription of 
genes encoding these proteins is reg-
ulated by a heterodimeric transcrip-
tion factor complex, which usually is 
the CLOCK protein bound to MOP3/
BMAL1. The CRY proteins associ-
ate with PERs and repress CLOCK/
BMAL1. As PERs and CRYs accumu-
late, their synthesis decreases; when 
PERs and CRYs are subsequently 
degraded, the transcription of their 
genes is derepressed. This cycle 
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Accurate clock timing requires 
the orderly transcription, transla-
tion, assembly, nuclear import, 
and then degradation of the PER 
and CRY proteins (Gallego and 
Virshup, 2007). A number of studies 
demonstrate that posttranslational 
modifications and targeted protein 
destruction are critical elements 
for correct timing. Two well-studied 
mammalian clock mutants—PER2/
FASPS (S662G) in humans and 
CKIεtau in hamsters—affect PER 
protein degradation. These circa-
dian mutations decrease the sta-
bility of the PER proteins, either by 
direct mutation of PER2 (S662G) or 
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